Heart-Wiring Pacemaker Cuts Serious Events in 702-Patient Trial

What did the trial find?

Researchers tracked a combined outcome of death, hospital admission for heart failure, or weakening of the heart muscle attributed to pacing. Over a typical follow-up of about 35 months:

• The outcome occurred in 16 patients assigned to left bundle-branch pacing.
• It occurred in 35 patients assigned to right ventricular pacing.
• The estimated four-year event rates were 8.5% versus 19.2%, after accounting for differences in how long each patient was observed. Not every participant had completed four years of follow-up.

The strongest difference concerned pacing-related weakening of the heart muscle. That complication was absent in the left bundle-branch group during the analysis, while it appeared in some patients receiving the conventional approach. Most participants entered the study with a normal measure of pumping strength, which makes prevention of later weakening an especially relevant result for them.

Takeaway: pacing through the heart's native wiring prevented the muscle-weakening complication that the standard approach can cause.

What are the caveats?

An independent monitoring group stopped the trial early after the new approach met its planned threshold for benefit. Early stopping is appropriate when a difference is compelling, but it also limits what the data can say about longer time horizons — extended follow-up remains valuable.

The technique also carries a practical demand: the implanting team must place the lead accurately in a particular area of the heart. That balance between procedural difficulty and benefit may shift depending on a patient's anatomy, overall condition and the experience of the team doing the implantation.

These results are preliminary in one further respect: devices and patients age. Longer observation can show how the leads perform over time and whether the advantage persists.

Takeaway: the benefit is real but measured over roughly three years, and it depends on precise lead placement.

What changes for practitioners?

For cardiologists treating people who need substantial pacing for heart block, the trial offers randomized evidence to raise in consultations: where the pacemaker starts the signal can matter as much as maintaining a steady rate. Patients with normal pumping strength at implantation stand to gain the most, since the newer approach prevented the weakening the standard method sometimes causes.

The study was reported by the First Affiliated Hospital of Nanjing Medical University. Further follow-up will determine how the technique holds up as patients and devices age.